X

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Probuphine in Patients With Opioid Dependence

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 31 Oct 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Buprenorphine (Primary)
Indications Opioid-related disorders
Focus Registrational; Therapeutic Use
Sponsors Titan Pharmaceuticals

Most Recent Events

22 Oct 2019 According to a Titan Pharmaceuticals media release, results from analysis of data from PRO-805, PRO-806, PRO-807, PRO-810 and PRO-811 Phase 3 clinical studies will be presented at the 10th American Conference on Pharmacometrics.
05 Mar 2014 New trial record
03 Mar 2014 Results have been published in the Journal of the American Medical Association (JAMA), according to a Titan Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com